The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins

Saisai Wei, Hongbo Wang, Chunwan Lu, Sarah Malmut, Jianqiao Zhang, Shumei Ren, Guohua Yu, Wei Wang, Dale D. Tang, Chunhong Yan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Mutant p53 proteins (mutp53) often acquire oncogenic activities, conferring drug resistance and/or promoting cancer cell migration and invasion. Although it has been well established that such a gain of function is mainly achieved through interaction with transcriptional regulators, thereby modulating cancer-associated gene expression, how the mutp53 function is regulated remains elusive. Here we report that activating transcription factor 3 (ATF3) bound common mutp53 (e.g. R175H and R273H) and, subsequently, suppressed their oncogenic activities. ATF3 repressed mutp53-induced NFKB2 expression and sensitized R175H-expressing cancer cells to cisplatin and etoposide treatments. Moreover, ATF3 appeared to suppress R175H- and R273H-mediated cancer cell migration and invasion as a consequence of preventing the transcription factor p63 from inactivation by mutp53. Accordingly, ATF3 promoted the expression of the metastasis suppressor SHARP1 in mutp53-expressing cells. An ATF3 mutant devoid of the mutp53-binding domain failed to disrupt the mutp53-p63 binding and, thus, lost the activity to suppress mutp53-mediated migration, suggesting that ATF3 binds to mutp53 to suppress its oncogenic function. In line with these results, we found that down-regulation of ATF3 expression correlated with lymph node metastasis in TP53-mutated human lung cancer. We conclude that ATF3 can suppress mutp53 oncogenic function, thereby contributing to tumor suppression in TP53-mutated cancer.

Original languageEnglish (US)
Pages (from-to)8947-8959
Number of pages13
JournalJournal of Biological Chemistry
Volume289
Issue number13
DOIs
StatePublished - Mar 30 2014

Fingerprint

Activating Transcription Factor 3
Mutant Proteins
Proteins
Cells
Neoplasms
Protein Binding
Cell Movement
Neoplasm Metastasis
Etoposide
Gene expression
Neoplasm Genes
Cisplatin
Tumors
Drug Resistance
Transcription Factors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. / Wei, Saisai; Wang, Hongbo; Lu, Chunwan; Malmut, Sarah; Zhang, Jianqiao; Ren, Shumei; Yu, Guohua; Wang, Wei; Tang, Dale D.; Yan, Chunhong.

In: Journal of Biological Chemistry, Vol. 289, No. 13, 30.03.2014, p. 8947-8959.

Research output: Contribution to journalArticle

Wei, Saisai ; Wang, Hongbo ; Lu, Chunwan ; Malmut, Sarah ; Zhang, Jianqiao ; Ren, Shumei ; Yu, Guohua ; Wang, Wei ; Tang, Dale D. ; Yan, Chunhong. / The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 13. pp. 8947-8959.
@article{de8e37198fd1471481e861cf66745682,
title = "The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins",
abstract = "Mutant p53 proteins (mutp53) often acquire oncogenic activities, conferring drug resistance and/or promoting cancer cell migration and invasion. Although it has been well established that such a gain of function is mainly achieved through interaction with transcriptional regulators, thereby modulating cancer-associated gene expression, how the mutp53 function is regulated remains elusive. Here we report that activating transcription factor 3 (ATF3) bound common mutp53 (e.g. R175H and R273H) and, subsequently, suppressed their oncogenic activities. ATF3 repressed mutp53-induced NFKB2 expression and sensitized R175H-expressing cancer cells to cisplatin and etoposide treatments. Moreover, ATF3 appeared to suppress R175H- and R273H-mediated cancer cell migration and invasion as a consequence of preventing the transcription factor p63 from inactivation by mutp53. Accordingly, ATF3 promoted the expression of the metastasis suppressor SHARP1 in mutp53-expressing cells. An ATF3 mutant devoid of the mutp53-binding domain failed to disrupt the mutp53-p63 binding and, thus, lost the activity to suppress mutp53-mediated migration, suggesting that ATF3 binds to mutp53 to suppress its oncogenic function. In line with these results, we found that down-regulation of ATF3 expression correlated with lymph node metastasis in TP53-mutated human lung cancer. We conclude that ATF3 can suppress mutp53 oncogenic function, thereby contributing to tumor suppression in TP53-mutated cancer.",
author = "Saisai Wei and Hongbo Wang and Chunwan Lu and Sarah Malmut and Jianqiao Zhang and Shumei Ren and Guohua Yu and Wei Wang and Tang, {Dale D.} and Chunhong Yan",
year = "2014",
month = "3",
day = "30",
doi = "10.1074/jbc.M113.503755",
language = "English (US)",
volume = "289",
pages = "8947--8959",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins

AU - Wei, Saisai

AU - Wang, Hongbo

AU - Lu, Chunwan

AU - Malmut, Sarah

AU - Zhang, Jianqiao

AU - Ren, Shumei

AU - Yu, Guohua

AU - Wang, Wei

AU - Tang, Dale D.

AU - Yan, Chunhong

PY - 2014/3/30

Y1 - 2014/3/30

N2 - Mutant p53 proteins (mutp53) often acquire oncogenic activities, conferring drug resistance and/or promoting cancer cell migration and invasion. Although it has been well established that such a gain of function is mainly achieved through interaction with transcriptional regulators, thereby modulating cancer-associated gene expression, how the mutp53 function is regulated remains elusive. Here we report that activating transcription factor 3 (ATF3) bound common mutp53 (e.g. R175H and R273H) and, subsequently, suppressed their oncogenic activities. ATF3 repressed mutp53-induced NFKB2 expression and sensitized R175H-expressing cancer cells to cisplatin and etoposide treatments. Moreover, ATF3 appeared to suppress R175H- and R273H-mediated cancer cell migration and invasion as a consequence of preventing the transcription factor p63 from inactivation by mutp53. Accordingly, ATF3 promoted the expression of the metastasis suppressor SHARP1 in mutp53-expressing cells. An ATF3 mutant devoid of the mutp53-binding domain failed to disrupt the mutp53-p63 binding and, thus, lost the activity to suppress mutp53-mediated migration, suggesting that ATF3 binds to mutp53 to suppress its oncogenic function. In line with these results, we found that down-regulation of ATF3 expression correlated with lymph node metastasis in TP53-mutated human lung cancer. We conclude that ATF3 can suppress mutp53 oncogenic function, thereby contributing to tumor suppression in TP53-mutated cancer.

AB - Mutant p53 proteins (mutp53) often acquire oncogenic activities, conferring drug resistance and/or promoting cancer cell migration and invasion. Although it has been well established that such a gain of function is mainly achieved through interaction with transcriptional regulators, thereby modulating cancer-associated gene expression, how the mutp53 function is regulated remains elusive. Here we report that activating transcription factor 3 (ATF3) bound common mutp53 (e.g. R175H and R273H) and, subsequently, suppressed their oncogenic activities. ATF3 repressed mutp53-induced NFKB2 expression and sensitized R175H-expressing cancer cells to cisplatin and etoposide treatments. Moreover, ATF3 appeared to suppress R175H- and R273H-mediated cancer cell migration and invasion as a consequence of preventing the transcription factor p63 from inactivation by mutp53. Accordingly, ATF3 promoted the expression of the metastasis suppressor SHARP1 in mutp53-expressing cells. An ATF3 mutant devoid of the mutp53-binding domain failed to disrupt the mutp53-p63 binding and, thus, lost the activity to suppress mutp53-mediated migration, suggesting that ATF3 binds to mutp53 to suppress its oncogenic function. In line with these results, we found that down-regulation of ATF3 expression correlated with lymph node metastasis in TP53-mutated human lung cancer. We conclude that ATF3 can suppress mutp53 oncogenic function, thereby contributing to tumor suppression in TP53-mutated cancer.

UR - http://www.scopus.com/inward/record.url?scp=84897377102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897377102&partnerID=8YFLogxK

U2 - 10.1074/jbc.M113.503755

DO - 10.1074/jbc.M113.503755

M3 - Article

C2 - 24554706

AN - SCOPUS:84897377102

VL - 289

SP - 8947

EP - 8959

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -